Fotemustine
Muphoran · Nitrosourea (alkylating)
Class delayed cumulative tubulointerstitial/ATN; usually mild; acute signal often really cisplatin.
Alimta · Pem
Antifolate · approved 2004 · 10 citations · FAERS AKI reporting ROR 3.88 (95% CI 3.69–4.08, 1,547 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
The slow burn — cumulative tubular toxicity that surfaces after many cycles.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Clinically relevant eGFR decline (≥25%) in ~21%; ~8% discontinue for nephrotoxicity. Cumulative-dose dependent.Source: de Rouw et al., Lung Cancer 2020
Cumulative — renal risk rises after roughly 10 cycles of exposure.
Distilled from: “Delayed / cumulative; risk rises after ~10 cycles.”
Acute pemetrexed ATN may recover, but cumulative/maintenance exposure drives insidious CKD upstaging with tubular dysfunction (nephrogenic diabetes insipidus, renal tubular acidosis) that is often only partially reversible after the drug is stopped.PMID 41614227 (opens PubMed in a new tab)
~10 cycles of exposure
Renal risk rises after roughly 10 cycles; clinically relevant eGFR decline (>=25%) occurs in ~21% and ~8% discontinue for nephrotoxicity.PMID 32505078 (opens PubMed in a new tab)
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
Recovery across agentsThis agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Clinically relevant (≥25%) eGFR decline in 21% during pemetrexed therapy — cumulative and dose-dependent (≥10 cycles: adjusted OR 5.66); a chronic tubulointerstitial injury that is often only partially reversible
Acute tubular injury/AKI reported in ~21% (6/29) of a single-center NSCLC cohort (baseline eGFR >45); biopsy-documented ATN with interstitial fibrosis in case reports PMID 24986522 (opens PubMed in a new tab)
Tubular electrolyte disturbances (nephrogenic diabetes insipidus, distal renal tubular acidosis, hypophosphatemia/hypokalemia) reported mainly at case level, not systematically quantified PMID 35190107 (opens PubMed in a new tab)
Exposure-correlated severe hyponatremia in a prospective PK cohort, with events during single-agent maintenance.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Chronic Interstitial Nephropathy strikes: Interstitium.
Chronic Interstitial Nephropathy
Slow, cumulative tubulointerstitial scarring — fibrosis, tubular atrophy and glomerulosclerosis with no discrete acute phase. The nitrosourea (carmustine/lomustine) lesion and delayed radioligand (radiation) nephropathy; often irreversible and detected only as a creeping creatinine months to years later.
Multitargeted antifolate inhibiting thymidylate synthase, DHFR and GARFT. Non-squamous NSCLC and mesothelioma, often as maintenance therapy.
Class-level context for the major non-renal toxicities of the Antifolate class.
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Hematologic
Cytopenias, thrombosis, TMA
Pulmonary
Pneumonitis, ILD, effusions, hypertension
9 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.
Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Pemetrexed for Injection is primarily excreted by the kidneys. Decreased renal function results in reduced clearance and greater exposure (AUC) to pemetrexed for injection compared with patients with normal renal function [Warnings and Precautions ( 5.2 , 5.6 ) and Clinical Pharmacology ( 12.3 )] . No dose is recommended for patients with creatinine clearance less than 45 mL/min [see Dosage and Administration ( 2.3 )].
Kidney rows of the label's dosage tables
From the Pemfexy label (Jun 2026) · DailyMed
The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. Educational only, not medical advice.
| Table 1: Recommended Dosage Modifications for Adverse Reactionsa | |
|---|---|
| Renal toxicity [see Warnings and Precautions (5.2)] | Withhold until creatinine clearance is 45 mL/min or greater. |
Everything below is FAERS — adverse events someone chose to report, about 39,105 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
7,335 of 39,105 reports
Reported with hospitalization
18,612 of 39,105 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 7,724 of the 39,105 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Pemetrexed sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Muphoran · Nitrosourea (alkylating)
Class delayed cumulative tubulointerstitial/ATN; usually mild; acute signal often really cisplatin.
Nipent · Purine analog (ADA inhibitor)
Renally cleared; dose-related acute kidney injury.
Nidran · Nitrosourea (alkylating)
Water-soluble nitrosourea; renal risk inferred at class level; cumulative delayed tubulointerstitial injury; DLT is myelosuppression.
Zelboraf · BRAF inhibitor
Strongest renal offender of the BRAF/MEK class: proximal tubular injury/Fanconi and early AKI.
Pluvicto · Radioligand therapy (PSMA)
PSMA-targeted radioligand for prostate cancer; renal radiation exposure and xerostomia.
Vidaza · Hypomethylating agent
Proximal (type 2) RTA / Fanconi-like tubulopathy; overt AKI uncommon.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Pemetrexed’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Pemetrexed; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 81 clinical records among all 112 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.